Biomarkers for immunotherapy in genitourinary malignancies

Urologic Oncology
Susan F Slovin

Abstract

Immunotherapy for genitourinary malignancies such as prostate, renal, and bladder cancers has experienced a resurgence since the development of 3 novel strategies: the autologous cellular product therapy, Sipuleucel-T for prostate cancer, the checkpoint inhibitors, anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed cell death ligand 1 (anti-PD1), and anti-programmed cell death ligand 1), respectively. These agents have led to strikingly durable responses in several of these solid tumors, but their efficacy has been inconsistent. Why all solid tumors are not equal in their response to these therapies is unclear. More importantly, changes in humoral or cellular responses which may reflect changes in a tumor's biology have been limited due to differences in immune monitoring and lack of consistency in established reliable immunologic endpoints. How to design immunologic end points that reflect a meaningful effect on the cancer remains a challenge for clinical trial development. The issues faced by clinical investigators and the current state of immune monitoring are discussed.

References

Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·R E ReiterO N Witte
Jan 10, 2004·The Journal of Urology·Kent G KrejciEugene D Kwon
Feb 3, 2004·Journal of Cellular Biochemistry·Arundhati Ghosh, Warren D W Heston
Aug 20, 2004·The New England Journal of Medicine·Massimo CristofanilliDaniel F Hayes
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Russell Katz
Feb 17, 2006·The New England Journal of Medicine·Helen GogasJohn M Kirkwood
Feb 17, 2006·The New England Journal of Medicine·Henry Koon, Michael Atkins
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven J CohenNeal J Meropol
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johann S de BonoDerek Raghavan
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Douglas G McNeelGeorge Wilding
Oct 15, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shuji OginoCharles S Fuchs
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck PagèsJérôme Galon
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel C DanilaHoward I Scher
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Jan 12, 2011·Cancer Immunology, Immunotherapy : CII·Mary L Disis
Jan 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth K Broussard, Mary L Disis
Jun 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel C DanilaHoward I Scher
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Oct 5, 2012·Journal of Translational Medicine·Jérôme GalonBernard A Fox
Mar 29, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S F SlovinT M Beer
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Jun 5, 2013·Frontiers in Oncology·Theresa L Whiteside
Oct 15, 2013·The Journal of Pathology·Jérôme GalonFranck Pagès
Aug 1, 2014·Nature·Ed Yong
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan

❮ Previous
Next ❯

Citations

Jan 6, 2016·International Journal of Molecular Sciences·Sergey V GudkovAndrei V Zvyagin
Jun 17, 2016·Future Oncology·Jeanny B Aragon-Ching, Donald L Trump
Nov 8, 2016·Expert Opinion on Biological Therapy·Panagiotis J VlachostergiosScott T Tagawa
Aug 31, 2019·Expert Review of Molecular Diagnostics·Ernest Y Lee, Rajan P Kulkarni
Oct 18, 2016·The Cancer Journal·Oladapo Yeku, Susan F Slovin

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B cells: Gene Expression

B lymphocytes are white blood cells that play a role in the adaptive immune system by secreting antibodies. Here is the latest research on gene expression in B cells.

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Current Oncology Reports
Alexandra Drakaki, David F McDermott
Proceedings of the National Academy of Sciences of the United States of America
KiBem KimShibin Zhou
The New England Journal of Medicine
Philip W KantoffIMPACT Study Investigators
© 2021 Meta ULC. All rights reserved